# Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

> **NCT01261728** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 57 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Gemcitabine and Cisplatin

## Key facts

- **NCT ID:** NCT01261728
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-14
- **Primary completion:** 2025-08-06
- **Final completion:** 2025-08-06
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01261728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01261728, "Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01261728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*